Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. - Wikidata - wikimedia - TriplyDB

Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver.

Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver.

http://www.wikidata.org/entity/Q44125748

about

TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus infection: therapeutic implications Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.Hepatocyte death: a clear and present danger.Hepatitis C virus sensitizes host cells to TRAIL-induced apoptosis by up-regulating DR4 and DR5 via a MEK1-dependent pathway Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.HIV infection increases HCV-induced hepatocyte apoptosis.A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.Foxp3 expression in liver correlates with the degree but not the cause of inflammation.Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis.Coinfection with HIV-1 and HCV--a one-two punch.The TRAIL to viral pathogenesis: the good, the bad and the ugly Thirteen-week Intravenous Toxicity Study of a Novel Humanized Anti-Human Death Receptor 5 Monoclonal Antibody, CS-1008, in Cynomolgus Monkeys.Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles.Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer.Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand.Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.Cellular and molecular mechanisms of liver injury.TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model.Midkine secretion protects Hep3B cells from cadmium induced cellular damage.Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study.A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis.Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease Death receptors as targets for anti-cancer therapy.Cell death pathways--potential therapeutic targets.Caspase inhibitors for the treatment of hepatitis C.Increased plasma levels of CK-18 as potential cell death biomarker in patients with HELLP syndrome TRAIL receptor signaling and therapeutics.Towards novel paradigms for cancer therapy.Cell death and nonalcoholic steatohepatitis: where is ballooning relevant?Mechanisms of cell death in acute liver failure.Systemic tumor-specific gene delivery.Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds.Engineering Stem Cells for Biomedical Applications.Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis.Targeting cell death signalling in cancer: minimising 'Collateral damage'.Chronic hepatitis C virus infection triggers spontaneous differential expression of biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononucleocytes.CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c-Jun N terminal kinase activation independent from the interferon pathway.

P2860

Q28539681-814D29F6-D3F0-4825-92A5-83D889067A39 Q33485621-22DA6ACC-88E7-4F02-B033-A0D3C5CB6530 Q33755829-665AE97C-259D-43B4-ADBA-7D7C55B26EAC Q34147508-33131AED-EA86-4807-9FA0-E57C7B0F0FE9 Q34291165-B964EAF2-4D51-4D09-9A0D-72F5D439544A Q34546374-FABDEF88-03F1-4A2C-9D2E-22D9B1B09450 Q34699457-53DEC5FE-953C-466C-A511-0F9F9EBA9B35 Q35038107-FF8513E2-65D6-4CA7-83E3-B8E1253A05D2 Q35104601-4099215E-4361-489A-BA7A-59C4B60EFBC1 Q35122049-35E4E981-A1EE-4878-AEAF-CA48E771FB2C Q35137038-8573D15F-A821-4943-86C7-7634859C2F68 Q35146349-A05429DF-8F99-4C1E-A618-184A94CB73A3 Q35603999-270BE34A-2D86-4D69-BFF5-86318EBC8893 Q36327671-35DDA1B1-C704-442B-A743-4F6E2C6BF9E8 Q36471345-7F3D8D12-AD1C-4646-83D6-C139D372A26C Q36777316-4B8762E2-0A16-441C-A30F-FC5ECF29A9A3 Q36825315-EC2D302F-9818-4BBF-A626-B1D6543B7C52 Q36908855-E02EEA40-2D64-4583-A0F7-A0C4BDF15A48 Q36943407-3FB291D7-E75A-4758-9E53-0536A962EF8E Q37028654-2F8CD692-0B4D-4FB9-A416-8249950371A5 Q37169731-1B124CE1-EF32-4FE7-A249-BAB1B0D86455 Q37185605-2A8EF565-68A7-4A96-A8B8-938CA86A620F Q37189403-BC513445-C6BE-4B99-9752-65170F20BC0E Q37211515-125D6872-7F6F-40F6-903E-17FF6B583EEA Q37310283-C2288F80-5A05-47C7-A8C0-336D5114C7EA Q37390893-3A6A5631-0498-4485-8B66-4A12985455E5 Q37557634-6B54BA9F-833A-4550-A620-B539515A2A25 Q37560275-3B414052-80FD-4891-8383-337D018B6AC5 Q37577467-702A1455-54AD-4664-8E70-C1B4DF6BFE4C Q37785559-1B5CC1CC-F9B6-4AFB-A905-2B90CFA0C101 Q37799251-FA373D7A-29EC-4270-BA68-3C3C096E498F Q37863134-18E95697-22B1-4153-A9E2-F3DA1A737C52 Q38000987-C839B609-7E6E-4A8F-BBCE-0837399AE7CB Q38137609-9688F500-7FEB-4A4C-9033-64CCF81BE236 Q38168505-778B9193-1C4C-41C1-AFA1-035EC6D42D3C Q38378499-AD1422C3-C5E1-474B-9549-4A132E8AB4D9 Q38799232-D1DFFA97-166A-45FC-81C0-A35A14170614 Q38824157-BC4B442D-6205-4CBC-A47C-F167F29349C3 Q38892529-F4F9653F-A562-42C7-892B-D0EEBE429D1A Q39311520-CF20E93F-21CA-4FA9-8C83-6482BBBF3E0B

P2860

Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver.

http://www.wikidata.org/entity/Q44125748

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Increased hepatotoxicity of tu ...... igand in diseased human liver.

@en

Increased hepatotoxicity of tu ...... igand in diseased human liver.

@nl

type

label

Increased hepatotoxicity of tu ...... igand in diseased human liver.

@en

Increased hepatotoxicity of tu ...... igand in diseased human liver.

@nl

prefLabel

Increased hepatotoxicity of tu ...... igand in diseased human liver.

@en

Increased hepatotoxicity of tu ...... igand in diseased human liver.

@nl

P1433

Q44125748-3A8BED8D-BE25-4CE9-9F0E-A2E910F4962E

P1476

Q44125748-53A49773-22C1-4F2F-9E98-FD921CE7FA8D

P2093

Q44125748-06E7D39B-6988-4187-8BF9-66E360FE61DA

Q44125748-14F01D1E-88C9-4076-8AE5-3B92A15D9DF8

Q44125748-35464F72-C998-4C7C-8538-CD15EAB73FF4

Q44125748-467BA6BB-C1BF-4757-984A-8C83489E5749

Q44125748-5826855D-1F73-4E53-96CE-08344D801869

Q44125748-9F566905-4143-401E-9E3F-E6E68FDC4E12

Q44125748-CC2D05A9-1A2D-4B31-8787-AC4546996B62

Q44125748-D3792F5D-E3E1-4993-9D58-70D229DA0AA9

Q44125748-D8041A34-8A10-4F88-AB7C-EA1EA08286A7

Q44125748-EF332A06-EAFA-407B-AEF1-EE0C9A3763F4

P304

Q44125748-B5CACED5-1B68-4A32-AE1E-3DBF2DCDE491

P31

Q44125748-475251DF-6D42-46D9-A3EA-FA97CDC241D0

P356

Q44125748-F8052207-0101-4C9E-9FCB-6273B7EF1DFF

P407

Q44125748-37B03B02-A0EA-43B5-A0E0-C7C9F1A1D040

P433

Q44125748-A2FF4DAE-02BA-4F15-95E0-495BBF3A92C9

P478

Q44125748-C2263759-8DC7-4E1B-9DF4-160523B6F840

P577

Q44125748-11D9CF99-3974-4145-8D46-05D91A483889

P5875

Q44125748-F093BF15-D2FC-4BB8-BC36-2AECD11DA50D

P698

Q44125748-B166C3F8-92D1-4CF2-9375-993AD269E10E

P921

Q44125748-CDE514EF-D3D5-41B8-A23E-66648CD09400

P356

P1433

P1476

Increased hepatotoxicity of tu ...... igand in diseased human liver.

@en

P2093

Frank Lehner

http://www.w3.org/2001/XMLSchema#string

Gerald M Cohen

http://www.w3.org/2001/XMLSchema#string

Heike Bantel

http://www.w3.org/2001/XMLSchema#string

Klaus Schulze-Osthoff

http://www.w3.org/2001/XMLSchema#string

Marion Macfarlane

http://www.w3.org/2001/XMLSchema#string

Matthias J Bahr

http://www.w3.org/2001/XMLSchema#string

Michael Ott

http://www.w3.org/2001/XMLSchema#string

Michael P Manns

http://www.w3.org/2001/XMLSchema#string

Ute Fischer

http://www.w3.org/2001/XMLSchema#string

Xandra Volkmann

http://www.w3.org/2001/XMLSchema#string

P304

1498-1508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.21846

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6135069

http://www.w3.org/2001/XMLSchema#string

P698

17705261

http://www.w3.org/2001/XMLSchema#string

P921